Literature DB >> 7925570

Presentation of exogenous antigens by macrophages: analysis of major histocompatibility complex class I and II presentation and regulation by cytokines.

M Kovacsovics-Bankowski1, K L Rock.   

Abstract

There is an antigen presenting cell (APC) in the lymphoid organs capable of presenting exogenous antigen (Ag) with major histocompatibility complex (MHC) class I molecules. This study was initiated to isolate clones of these APC to definitively establish their phenotype and to further study their properties. Murine bone marrow macrophages (BM M psi) were immortalized by overexpression myc and raf oncogenes. Five BM M psi cell lines were generated that are phagocytic and expressed at their surface M psi differentiation Ag. All five cell lines processed and presented exogenous ovalbumin (OVA) with MHC class I molecules. They all presented OVA-linked to a phagocytic substrate 10(2)-10(4)-fold more efficiently than soluble Ag. Clonal isolates of two of the M psi cell lines had an identical phenotype and functional properties as the uncloned lines. These results definitively establish that M psi are APC with the capacity of presenting exogenous Ag with MHC class I molecules. Interferon (IFN)-gamma interleukin-4, granulocyte-macrophage colony stimulating factor and lipopolysaccharide either alone or in combination induced little or no augmentation and in some cases decreased presentation of exogenous OVA with MHC class I. In contrast, all of M psi activating factors increased MHC class I expression. Moreover, IFN-gamma increased the presentation of cytosolic OVA, demonstrating differences between the presentation of cytosolic Ag versus exogenous Ag with MHC class I. Finally, some lines constitutively processed and presented exogenous OVA with MHC class II while others only presented after stimulation with IFN-gamma. These results demonstrate that the pathways involved in the presentation of exogenous Ag with MHC class I and class II are independently regulated and that a cloned cell is capable of presenting exogenous Ag through both pathways.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7925570     DOI: 10.1002/eji.1830241024

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  22 in total

1.  Cellular protein is the source of cross-priming antigen in vivo.

Authors:  Lianjun Shen; Kenneth L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

2.  Engineered Materials for Cancer Immunotherapy.

Authors:  Alexander S Cheung; David J Mooney
Journal:  Nano Today       Date:  2015-08-01       Impact factor: 20.722

Review 3.  Plasmid DNA vaccination: mechanism of antigen presentation.

Authors:  M Corr; H Tighe
Journal:  Springer Semin Immunopathol       Date:  1997

4.  Thymoquinone from nutraceutical black cumin oil activates Neu4 sialidase in live macrophage, dendritic, and normal and type I sialidosis human fibroblast cells via GPCR Galphai proteins and matrix metalloproteinase-9.

Authors:  Trisha M Finlay; Preethi Jayanth; Schammim Ray Amith; Alanna Gilmour; Christina Guzzo; Katrina Gee; Rudi Beyaert; Myron R Szewczuk
Journal:  Glycoconj J       Date:  2010-03-06       Impact factor: 2.916

5.  Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice.

Authors:  S B Justin Wong; Robert F Siliciano
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  Neu1 sialidase and matrix metalloproteinase-9 cross-talk is essential for Toll-like receptor activation and cellular signaling.

Authors:  Samar Abdulkhalek; Schammim Ray Amith; Susan L Franchuk; Preethi Jayanth; Merry Guo; Trisha Finlay; Alanna Gilmour; Christina Guzzo; Katrina Gee; Rudi Beyaert; Myron R Szewczuk
Journal:  J Biol Chem       Date:  2011-08-26       Impact factor: 5.157

7.  Extending the CD4(+) T-cell epitope specificity of the Th1 immune response to an antigen using a Salmonella enterica serovar typhimurium delivery vehicle.

Authors:  R Lo-Man; J P Langeveld; E Dériaud; M Jehanno; M Rojas; J M Clément; R H Meloen; M Hofnung; C Leclerc
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

8.  Adjuvant-Loaded Subcellular Vesicles Derived From Disrupted Cancer Cells for Cancer Vaccination.

Authors:  Alexander S Cheung; Sandeep T Koshy; Alexander G Stafford; Maartje M C Bastings; David J Mooney
Journal:  Small       Date:  2016-03-08       Impact factor: 13.281

9.  Human immunodeficiency virus type 1 Gag p24 alters the composition of immunoproteasomes and affects antigen presentation.

Authors:  Nicholas J Steers; Kristina K Peachman; Sasha R McClain; Carl R Alving; Mangala Rao
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

10.  Dependence of pathogen molecule-induced toll-like receptor activation and cell function on Neu1 sialidase.

Authors:  Schammim Ray Amith; Preethi Jayanth; Susan Franchuk; Sarah Siddiqui; Volkan Seyrantepe; Katrina Gee; Sameh Basta; Rudi Beyaert; Alexey V Pshezhetsky; Myron R Szewczuk
Journal:  Glycoconj J       Date:  2009-12       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.